The agricultural biologicals industry is entering a new phase in 2026 as growing adoption no longer guarantees proportional value for manufacturers, distributors or farmers. Manel Cervera, managing partner at DunhamTrimmer Bio Intelligence, argues that rising competition, price pressure and product commoditization are changing where agricultural value is created. For U.S. agriculture, the shift matters because growers facing tighter margins increasingly need crop inputs to prove not only that they work, but that they can deliver consistent economic and agronomic performance within existing production systems.

Biofertilizers, biostimulants and biocontrol products remain positioned for growth, but they are reaching different levels of market maturity and facing similar commercial barriers. According to Cervera, biological nitrogen fixation and technologies designed to improve nutrient-use efficiency have significant potential. Yet variable performance across environments and growing seasons, limited integration with conventional agronomic programs and the need to change farmer practices can slow adoption. Scientific innovation alone, therefore, may not be enough to turn a promising biological technology into a scalable farm input.

Biologicals

Biologicals Gain Ground in Latin America, but Where Do They Really Fit in the Grower's Toolbox?

Biologicals Must Move Beyond the Stand-Alone Product

Biostimulants face another challenge: differentiation. Relatively low barriers to entry, competing products with similar characteristics and continued price pressure can make it harder for companies to maintain a premium. Cervera says the challenge is converting scientifically supported product attributes into commercial advantages capable of achieving scale. The question for the industry is shifting from how quickly biologicals can expand to which technologies can capture value as the category becomes more competitive. That distinction becomes particularly important when growers scrutinize every additional input in their crop budgets.

Biocontrol provides another example of this changing equation. DunhamTrimmer's analysis indicates that increasing adoption does not necessarily mean every participant in the supply chain captures value at the same rate. The underlying lesson extends across biological categories: acreage growth and value creation are not the same thing. Companies must increasingly demonstrate why their technology deserves a place within a production program, while farmers and crop advisers need evidence that an additional input can provide measurable benefits without introducing unnecessary operational complexity.

That pressure is helping move the industry toward what Cervera describes as functional nutrition. Rather than viewing nutrients exclusively as individual products, this approach considers how nutrition can interact with delivery systems, biological processes, stress management and other components of crop production. Formulation, microbial interactions, compatibility and application become part of the technology's value proposition. In this model, innovation increasingly resides not only in what is inside a container, but in how effectively that technology performs alongside the other inputs and management decisions already used on the farm.

The shift could also change how farmers evaluate performance. Maximum theoretical yield remains important, but stability, resilience, nutrient-use efficiency, predictability and operational reliability can carry significant economic value when weather and farm economics are volatile. Cervera argues that consistent performance may become as important as maximum yield potential under uncertain conditions. For growers managing input costs, the relevant calculation is increasingly whether a technology can repeatedly generate enough agronomic and economic value to justify its place in the production system, rather than whether it produced an exceptional result in an isolated trial.

The Next Competitive Edge May Be Integration

Operational simplicity is becoming part of that equation. A biological product can demonstrate agronomic efficacy and still struggle commercially if it requires complicated application procedures, creates compatibility problems or lacks adequate local validation. A technology must be executable under commercial farming conditions, not merely effective under controlled testing. That raises the importance of tank-mix compatibility, timing, application logistics, labor requirements and interaction with fertility and crop protection programs - factors that can ultimately determine whether an innovation moves from successful trials to broad adoption.

Cervera summarizes the emerging concept by arguing that farmers do not manage product categories independently; they manage an agricultural "stack." That stack can include genetics, fertility, biologicals, adjuvants, crop protection, timing, environmental conditions, analytics, logistics and labor. Value increasingly depends on how those components work together. For U.S. producers, this perspective could become particularly relevant as precision agriculture generates more information about field variability while farmers simultaneously seek to improve input efficiency and protect yields without adding unnecessary cost or complexity.

The transformation could also strengthen the role of ag retailers, crop consultants and co-ops. As biological portfolios expand, distributors can move beyond product delivery and become technical translators, local validators and solution integrators. Their ability to determine compatibility, interpret field results and simplify recommendations could help growers navigate an increasingly crowded market. Selling another biological product may become less valuable than helping a farmer determine where, when and why a biological technology belongs within an existing crop program.

For manufacturers, the competitive frontier therefore appears to be moving beyond product discovery alone. DunhamTrimmer identifies integrated systems, operational simplicity and evidence-backed functionality as areas likely to concentrate future value creation. The implications extend throughout the agricultural supply chain: biological technologies may continue gaining acres, but the companies and distribution channels positioned to benefit most could be those capable of demonstrating repeatable field performance and economic relevance while fitting technologies into practical production systems.

The broader question for biologicals is consequently changing. Market growth remains important, but capturing sustainable value will depend increasingly on integration, consistency and farm-level economics. For growers, that could produce a more demanding standard for new crop inputs: not simply whether a biostimulant, biofertilizer or biocontrol product works, but whether it works reliably with the rest of the system and produces sufficient value to earn another line in the crop budget.